Investors

Event Calendar

 

Upcoming Events

Year End 2022 Financial Results 31 March 2023

Read more


    Annual General Meeting 2023

    29th June 2023 10:30am CEST Venue: TBD
    Read more


      Half Year 2023 Financial Results week commencing 14 August 2023

      Read more


        Past Events

        Q3 2022 Financial Results Thursday 1st December, 2022

        December 4, 2022

        Read more

        Q2 2022 Financial Results week of 15 August 2022

        August 12, 2022

        Read more

        ObsEva to Present at the H.C. Wainwright Global Investment 2022 Conference

        May 28, 2022

        Read more
        1 2 3 31

        General Meetings

        ObsEva Annual General Meeting 2020

        June 9, 2020

        Read more

        ObsEva Annual General Meeting 2019

        May 8, 2019

        Read more
        1 2 3 4
         
         

        Sign up for news

         
         

          * Type:


          InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












          Read our privacy policy here.


           

          Are you sure you want to leave ObsEva.com?

          We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

          Continue to link

          Disclaimer

          Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

          Continue

          Disclaimer

          Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

          Continue